CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Salix Pharmaceuticals Inc. v. Novel Laboratories Inc.

1:15-cv-00027

Overview

Case Number 1:15-cv-00027
Filing Date 2015-01-08
Status Terminated
Termination Date 2017-07-31
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Novel Laboratories Inc. Operating Company

Represented By

1 Attorneys Listed

Adam Wyatt Poff

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6600

Rodney Square, 1000 North King Street

Plaintiff

Dr. Falk Pharma GmbH Operating Company

Represented By

4 Attorneys Listed

Kristen Healey Cramer

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4320
Fax: +1 (302) 777-4224

1313 North Market Street, Suite 1200

Mary W. Bourke

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4320

1313 North Market Street, Suite 1200

Daniel Marcus Attaway

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4365

1313 North Market Street, Suite 1200

Dana Kathryn Severance

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4329
Fax: +1 (302) 661-7710

1313 North Market Street, Suite 1200

Salix Pharmaceuticals Inc. Operating Company

Represented By

4 Attorneys Listed

Kristen Healey Cramer

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4320
Fax: +1 (302) 777-4224

1313 North Market Street, Suite 1200

Mary W. Bourke

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4320

1313 North Market Street, Suite 1200

Daniel Marcus Attaway

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4365

1313 North Market Street, Suite 1200

Dana Kathryn Severance

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4329
Fax: +1 (302) 661-7710

1313 North Market Street, Suite 1200

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 3 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 3 proceedings
πŸ›οΈ
USPTO PTAB Trials 3 proceedings
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (3): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (6 found):
PTAB: 3 U.S. Courts: 3
USPTO PTAB Trial 2016-07-11
IPR2016-01409

MycoNovo, Inc. et al. v. Salix Pharmaceuticals, Ltd. et al.

Asserted Patent
Status: Terminated
USPTO PTAB Trial 2016-07-08
IPR2016-01386

Mylan Pharmaceuticals Inc. et al. v. Salix Pharmaceuticals, Ltd. et al.

Asserted Patent
Status: Terminated
USPTO PTAB Trial 2015-12-08
IPR2016-00297

GeneriCo, LLC et al. v. SALIX PHARMACEUTICALS, LTD. et al.

Asserted Patent
Status: Final Written Decision
U.S. District Court 2017-03-27
1:17-cv-00329

Salix Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc.

Asserted Patent
Status: DED
U.S. District Court 2015-06-26
1:15-cv-00109

Salix Pharmaceuticals, Inc v. Mylan Pharmaceuticals, Inc.

Asserted Patent
Status: WVND
U.S. District Court 2014-02-18
1:14-cv-00213

Salix Pharmaceuticals Inc. v. G & W Laboratories, Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8865688
Compositions and methods for treatment of bowel diseases with granulated mesalamine
Filed: 2009-10-02
Issued: 2014-10-21
Active (3.4 yrs remaining) +211d PTA
Expires: 2030-05-01

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+211 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(25 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Novel Laboratories Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1652279.) - filed by Dr. Falk Pharma GmbH, Salix Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(mas) (Entered: 01/09/2015)

Entry #1 • 2015-01-08
1
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Novel Laboratories Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1652279.) - filed by Dr. Falk Pharma GmbH, Salix Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(mas) (Entered: 01/09/2015)

Entry #1 • 2015-01-08
2
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Novel Laboratories Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1652279.) - filed by Dr. Falk Pharma GmbH, Salix Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(mas) (Entered: 01/09/2015)

Entry #1 • 2015-01-08
2

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mas) (Entered: 01/09/2015)

Entry #2 • 2015-01-08
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/19/2014. Date of Expiration of Patent: 05/01/2030.Thirty Month Stay Deadline: 7/6/2016. (mas) (Entered: 01/09/2015)

Entry #3 • 2015-01-08
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc